Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults

Journal of Infectious Diseases

Volumn 208, Issue 9, 2013, Pages 1375-1385

  Mullane, Kathleen M ^a   Winston, Drew J ^b   Wertheim, Michael S ^c   Betts, Robert F ^d   Poretz, Donald M ^e   Camacho, Luis H ^f   Pergam, Steven A ^g   Mullane, Michael R ^h   Stek, Jon E ⁱ   Sterling, Tina M ⁱ   Zhao, Yanli ⁱ   Manoff, Susan B ⁱ   Annunziato, Paula W ⁱ  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c Hematology Oncology Associates of Treasure Coast   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e Clinical Alliance For Research and Education Infectious Diseases   (United States)

^f Oncology Consultants   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h Stroger Hospital   (United States)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

herpes zoster; immunocompromised adults; zoster vaccine

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN; PLACEBO; VARICELLA ZOSTER VACCINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GEOMETRIC MEAN FOLD RISE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR;

HERPES ZOSTER; IMMUNOCOMPROMISED ADULTS; ZOSTER VACCINE;

ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HERPES ZOSTER VACCINE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VACCINATION; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84885412725     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit344     Document Type: Article

References (34)

1. Cohen JI. HZ vaccine in immunocompromised patients. J Infect Dis 2008; 197:S237-41
2. Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology 2006; 71:164-7
3. Feld R, Evans WK, DeBoer G. Herpes zoster in patients with small-cell carcinoma of the lung receiving combined modality treatment. Ann Intern Med 1980; 93:282-3
4. Huberman M, Fossieck BE Jr, Bunn PA Jr, Cohen MH, Ihde DC, Minna J. Herpes zoster and small cell bronchogenic carcinoma. Am J Med 1980; 68:214-8.13
5. Schimpff S, Serpick A, Stoler B, et al. Varicella-zoster infection in patients with cancer. Ann Intern Med 1972; 76:241-54
6. Wade JC. Viral infections in patients with hematological malignancies. Hematology 2006; 1:368-74
7. Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of varicellazoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9:976-80
8. Rusthoven JJ, Ahlgren P, Elhakim T, Pinfold P, Stewart L, Feld R. Varicella-zoster infection in adult cancer patients. Arch Intern Med 1988; 148:1561-6
9. Engels EA, Rosenberg PS, Biggar RJ. Zoster incidence in human immunodeficiency virus-infected hemophiliacs and homosexual men, 1984-1997. J Infect Dis 1999; 180:1784-9
10. U.S. Food and Drug Administration. Approved Products: Zostavax. Merck & Co., Inc., Whitehouse Station, NJ. http://www.fda.gov/ downloads/biologicsbloodvaccines/vaccines/approved products/ucm132831.pdf. Accessed 2 August 2012
11. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84
12. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922-928
13. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176:578-85
14. Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347:26-34
15. Harbecke R, Oxman MN, Arnold BA, et al. A real-Time PCR assay to identify and discriminate among wild-Type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses. J Med Virol 2009; 81: 1310-22
16. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 2001; 8:871-9
17. Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW. Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods 1986; 14:177-88
18. Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol 1990; 32:189-93
19. Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991; 9:111-6
20. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26
21. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404-13
22. Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya 2000; 62:134-48
23. Holmberg L, Kikuchi K, Gooley TA, et al. Gastrointestinal graft-versushost disease in recipients of autologous hematopoietic stem cells: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2006; 12:226-34
24. Rand KH, Rasmussen LE, Pollard RB, Arvin A, Merigan TC. Cellular immunity and herpes virus infections in cardiac transplant patients. N Engl J Med 1976; 296:1372-7
25. Sokal JE, Firat D. Varicella-zoster infection in Hodgkin's disease. Am J Med 1965; 39:452-63
26. Antonelli MAS, Moreland LW, Brick JE. Herpes zoster in patients with rheumatoid arthritis treated with weekly low-Dose methotrexate. Am J Med 1991; 90:295-8
27. Levin MJ, Oxman MN, Zhang JH, et al. Varicella zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197:825-35
28. Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine 2012; 30:904-10
29. Talmadge JE, Reed E, Ino K, et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997; 19:161-72
30. Diviné M, Boutolleau D, Delfau-Larue MH, et al. Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol 1999; 105:349-60
31. Glesby MJ, Moore RD, Chaisson RE. Zidovudine Epidemiology Study Group. Herpes zoster in patients with advanced human immunodeficiency virus infection treated with zidovudine. J Infect Dis 1993; 168:1264-8
32. Vafai A, Berger M. Zoster in patients infected with HIV: A review. Am J Med Sci 2001; 321:372-80
33. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2005; 40:169-74
34. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-45